Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Self-prescribed Ivermectin use is associated with a lower rate of seroconversion in health care workers diagnosed with COVID, in a dose-dependent response

Pedroso et al., The Brazilian Journal of Infectious Diseases, doi:10.1016/j.bjid.2021.101603
Aug 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now known with p < 0.00000000001 from 100 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Retrospective 45 healthcare workers in Brazil, showing lower creation of antibodies with multiple doses of ivermectin, which may be expected due to the antiviral activity as demonstrated in multiple studies. Authors appear unaware of these studies, citing only earlier in vitro research, which they misinterpret to suggest that therapeutic concentrations are not reached (for details on why this is incorrect see Authors combine no dose and one dose. Clinical outcomes and timing of treatment are not provided.
Pedroso et al., 12 Aug 2021, peer-reviewed, 11 authors.
This PaperIvermectinAll
Self-prescribed Ivermectin use is associated with a lower rate of seroconversion in health care workers diagnosed with COVID, in a dose-dependent response
Célia Pedroso, Sara Vaz, Eduardo Martins Netto, Daniele Souza, Felice Deminco, Rafaela Mayoral, Eliana Menezes, Ana Patricia Amancio Da Cunha, Andres Moreira-Soto, Jan Felix Drexler, Carlos Brites
The Brazilian Journal of Infectious Diseases, doi:10.1016/j.bjid.2021.101603
Background: Over-the-counter use of ivermectin amongst other drugs as SARS-CoV-2 treatment has been increasingly common, despite the lack of evidence on its clinical efficacy. Objective: To evaluate the effect of ivermectin use on production of antibodies against SARS-CoV-2 in health care workers (HCW) diagnosed with COVID-19 and of Th1/Th2 cytokines by stimulated peripheral blood mononuclear cells of the same cohort (PBMCs). Methods: This cross-sectional study evaluated seroconversion and neutralizing antibodies production in HCW at Complexo Hospitalar Universit ario Professor Edgard Santos (Salvador, Brazil), diagnosed with COVID-19 from May to July, 2020, as well as in vitro production of antibody against SARS-CoV-2 and Th1/Th2 cytokines. Analyses were performed between December 2020 and February 2021. Participants were stratified according to the use of ivermectin (≤ 1 dose vs. multiple doses) for treatment of COVID-19. Results: 45 HCW were included (62% women). Mean age was 39 years, and disease severity was similar across groups. Neutralizing antibodies were detected less frequently in multiple doses (70%) vs. ≤ 1 dose (97%) groups, p = 0.02). PBMCs of patients in multiple doses group also were less likely to produce antibodies against SARS-CoV-2 following in vitro stimulation with purified spike protein in comparison with patients in ≤ 1 dose group (p < 0.001). PBMCs production of Th1/Th2 cytokines levels was similar across groups. Abdominal pain (15% vs 46%, p = 0.04), diarrhea (21% vs. 55%, p = 0.05) and taste perversion (0% vs. 18%, p = 0.05) were more frequently reported by participants that used multiple doses of ivermectin. Conclusions: Although there was no evidence for differential disease severity upon ivermectin use for treatment of COVID-19 it was associated with more gastro-intestinal side-effects and impairment of anti-SARS-CoV2 antibodies production, in a dose dependent manner.
Amadori, De Rossi, Giaquinto, Faulkner-Valle, None
El-Tahtawy, Glue, Andrews, Mardekian, Amsden, None
Gallardo, Teiti, Rochaix, Macrocyclic lactones block 205 melanoma growth, metastases development and potentiate 206 activity of anti-BRAF V600 inhibitors, Clin Skin Cancer
Gonzalez De Castro, Clarke, Al-Lazikani, Workman, None
Guzzo, Safety, tolerability, and pharmacokinetics of 225 escalating high doses of ivermectin in healthy adult subjects
Knirsch, The effect of azithromycin on ivermectin 229 pharmacokinetics − a population pharmacokinetic model
Rusconi, Santambrogio, Marco, Lack of in vitro 201 anti-gp160 antibody production is a correlate of 202 nonprogression among HIV type 1-infected individuals, AIDS
Tang, Hu, Wang, Ivermectin, a potential 213 anticancer drug derived from an antiparasitic drug, Pharmacol
Tay, Fraser, Chan, Nuclear localization of 217 dengue virus (DENV) 1-4 non-structural protein 5; protection 218 against all 4 DENV serotypes by the inhibitor Ivermectin
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, None
Zacchello, Bianchi, In-vitro production of HIV-197 specific antibody in children at risk of AIDS, Lancet, doi:10.1016/s0140-6736(88)91603-0
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop